Your browser doesn't support javascript.
loading
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Barda, Noam; Dagan, Noa; Cohen, Cyrille; Hernán, Miguel A; Lipsitch, Marc; Kohane, Isaac S; Reis, Ben Y; Balicer, Ran D.
Affiliation
  • Barda N; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel; Software and Information Systems Engineering, Ben Gurion University of the Negev, Be'er Sheva, Israel; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA; The Ivan and Francesca Berko
  • Dagan N; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel; Software and Information Systems Engineering, Ben Gurion University of the Negev, Be'er Sheva, Israel; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA; The Ivan and Francesca Berko
  • Cohen C; The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
  • Hernán MA; Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA; CAUSALab, Harvard T H Chan School of Public Health, Boston, MA, USA.
  • Lipsitch M; Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Center for Communicable Disease Dynamics, Harvard T H Chan School of Public Health, Boston, MA, USA.
  • Kohane IS; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA; The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Reis BY; The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute, Boston, MA, USA; Predictive Medicine Group, Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Balicer RD; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel; School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Be'er Sheva, Israel; The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School an
Lancet ; 398(10316): 2093-2100, 2021 12 04.
Article in En | MEDLINE | ID: mdl-34756184
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunization, Secondary / COVID-19 / Vaccine Efficacy / BNT162 Vaccine Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Lancet Year: 2021 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunization, Secondary / COVID-19 / Vaccine Efficacy / BNT162 Vaccine Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Lancet Year: 2021 Type: Article